A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Status:
Completed
Trial end date:
2017-08-17
Target enrollment:
Participant gender:
Summary
This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and
efficacy of orally administered ATR-101 in subjects with classic congenital adrenal
hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to
6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of
5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.